[Form 4] Pagaya Technologies Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. (RCKT) – Form 144 filing discloses that insider Aaron Ondrey intends to sell 1,477 common shares through Fidelity Brokerage Services on 07 July 2025. The planned transaction is valued at approximately $4,256.42, based on the market price at the time of filing. The shares were acquired via restricted-stock vesting on 01 July 2025 and constitute less than 0.002% of the 107.7 million shares outstanding. The insider previously sold 7,489 shares on 04 Apr 2025 for $39,646.77.

The filing is a routine notification under Rule 144 and does not, by itself, indicate any change to Rocket Pharmaceuticals’ fundamentals. The modest size of the transaction suggests minimal dilution or ownership impact for existing shareholders.

Positive

• None.

Negative

• Insider selling activity (1,477 shares now; 7,489 shares in April) may be viewed cautiously by some investors, although the volume is immaterial.

Insights

Securities Analyst

TL;DR: Small insider sale (1,477 shares) is routine and immaterial; neutral impact on valuation.

The sale represents an insignificant fraction of RCKT’s float and follows a prior 7,489-share disposal in April. The shares stem from recent RSU vesting, typical for employee compensation. With aggregate value below $50k, liquidity and ownership structure remain largely unchanged. No additional information on financial performance or strategic direction is provided, so the filing is best viewed as administrative. Investors should monitor future insider activity for patterns but need not adjust models on this disclosure alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perros Evangelos

(Last) (First) (Middle)

C/O PAGAYA TECHNOLOGIES LTD.

335 MADISON AVENUE, 16TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pagaya Technologies Ltd. [ PGY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	07/01/2025	07/01/2025	M		22,766	A	$0	95,625	D
Class A Ordinary Share	07/02/2025	07/02/2025	S(1)		12,755	D	$22.57	82,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	07/01/2025	07/01/2025	M			22,766	(2)	(2)	Class A Ordinary Share	22,766	$0	136,594	D

Explanation of Responses:

1. Sale of securities was necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory award.

2. 1/6th of the total 273,224 restricted stock units subject to this award vest each on August 1, 2024 and January 1, 2025, and the remaining 2/3rd of the grant vests over the following 24 months in equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025, January 1, 2026, April 1, 2026, July 1, 2026, October 1, 2026 and January 1, 2027.

Remarks:

	/s/ Natalie Wilmore, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rocket Pharmaceuticals (RCKT) shares are being sold under this Form 144?

1,477 common shares are planned for sale.

What is the estimated market value of the planned sale?

Approximately $4,256.42 based on the filing.

When is the insider sale expected to occur?

On or about 07 July 2025.

What proportion of RCKT’s outstanding shares does the sale represent?

Less than 0.002% of the 107,737,919 shares outstanding.

Were there recent insider sales prior to this notice?

Yes. 7,489 shares were sold on 04 Apr 2025 for $39,646.77.